Stephen Keefe
Overview
Explore the profile of Stephen Keefe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makker V, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller D, et al.
N Engl J Med
. 2022 Jan;
386(5):437-448.
PMID: 35045221
Background: Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced...
2.
Nishio S, Matsumoto K, Takehara K, Kawamura N, Hasegawa K, Takeshima N, et al.
Cancer Sci
. 2020 Feb;
111(4):1324-1332.
PMID: 32012411
Interim results from the two-cohort, phase 2 KEYNOTE-100 study (NCT02674061) of 376 patients with previously treated advanced recurrent ovarian cancer (ROC) showed that pembrolizumab monotherapy was associated with an objective...
3.
Freshwater T, Li H, Valiathan C, Li M, Perini R, Bracco O, et al.
Am J Clin Oncol
. 2019 Sep;
42(10):802-809.
PMID: 31503064
Objective: The purpose of this systematic literature review (SLR) and meta-analysis was to compile the response of historic treatment options in first-line settings for patient populations who are cisplatin ineligible....
4.
Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, et al.
Eur Urol Oncol
. 2019 Aug;
2(5):565-571.
PMID: 31412011
Background: There is an unmet need for effective therapies for patients with advanced or metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatin-ineligible patients experience a high frequency of adverse...
5.
Catino A, Hubbard R, Chirinos J, Townsend R, Keefe S, Haas N, et al.
Circ Heart Fail
. 2018 Apr;
11(3):e004408.
PMID: 29664405
Background: Sunitinib, used widely in metastatic renal cell carcinoma, can result in hypertension, left ventricular dysfunction, and heart failure. However, the relationships between vascular function and cardiac dysfunction with sunitinib...
6.
Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, et al.
Clin Cancer Res
. 2017 Feb;
23(14):3601-3609.
PMID: 28196874
To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. In a multicenter prospective study of 90 patients...
7.
Grossman H, Lamm D, Kamat A, Keefe S, Taylor 3rd J, Ingersoll M
J Immunother
. 2016 Jul;
39(8):291-7.
PMID: 27428265
Bladder cancer is understudied despite its high prevalence and its remarkable response to immunotherapy. Indeed, funding for studies to explore mechanisms of tumor immunity and novel new therapeutics is disproportionately...
8.
Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz S, Vaughn D
Cancer Res Treat
. 2015 Dec;
48(3):1084-91.
PMID: 26639198
Purpose: We sought to investigate the safety and efficacy of gemcitabine, cisplatin, and lapatinib (GCL) as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) planned for radical cystectomy. Materials...
9.
Maniar T, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, et al.
Cancer Biol Ther
. 2007 Oct;
6(10):1525-31.
PMID: 17952026
Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation. Brain tumors, most commonly meningiomas, are...